Description

Moexipril-d3 is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects[1]-[4].–Applications-Neuroscience-Neurodegeneration-Formula-C27H31D3N2O7-Citation–References-[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Chrysant, S.G. and G.S. Chrysant, Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol, 2004. 44(8): p. 827-36.|[3]Friehe H, et al. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung. 1997 Feb. 47(2):132-44.|[4]Edling O, et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63.|[5]Ravati A, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373(1):21-33.-CASNumber–MolecularWeight-501.59-Compound Purity–SMILES-O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C([2H])([2H])[2H])=O)CC3=C(C=C(OC)C(OC)=C3)C1)O-Research_Area-Neurological Disease; Cardiovascular Disease-Solubility-10 mM in DMSO-Target-Angiotensin-converting Enzyme (ACE);Apoptosis;Isotope-Labeled Compounds-Isoform–Pathway-Apoptosis;Metabolic Enzyme/Protease;Others-MCE Product type-Isotope-Labeled Compounds